TAVALISSE FDA approval date

The FDA approved TAVALISSE on 17 Apr 2018.

FDA approval date
17 Apr 2018

Drug identity has not yet been verified against registry records

Also recorded as FOSTAMATINIB DISODIUM

Included trials

No linked trials for this drug yet. Browse all trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2018-04-17DayTAVALISSEFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA209299", "applicant_as_listed_by_fda": "RIGEL PHARMS", "brand_names": ["TAVALISSE"], "active_ingredients": ["FOSTAMATINIB DISODIUM"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20180417", "matched_on": "drug record created from this FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026